Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation
Status:
Not yet recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
The recommended adjuvant therapy for stage Ⅱa-Ⅲb Non-small cell lung cancer (NSCLC) were
perioperative chemotherapy. The adjuvant or neoadjuvant chemotherapy for early stage lung
cancer improved about 5% 5-year survival. As for advanced NSCLC with epidermal growth factor
receptor (EGFR) activating mutation, epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) combination with chemotherapy had improved progression-free survival
(PFS) compared with EGFR-TKI alone. We propose this trial of Neoadjuvant Afatinib Combination
With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation, which would maximize
benefit early in a patient's treatment course. At the same time, dynamic
18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) was used to
evaluate the standardized uptake value (SUV) and uptake rate constant (Ki) changes of lesions
before and after treatment, so as to accurately and quantitatively monitor the tumor response
of different therapy.